Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Costs and Expenses:
General and administrative	$ 7,120,000	$ 9,858,000
Research and development	14,311,000	11,723,000
Total Operating Costs and Expenses	21,431,000	21,581,000
Loss from Operations	(21,431,000)	(21,581,000)
Other Income:
Foreign currency exchange gain (loss)	3,000	(41,000)
Interest income	1,439,000	512,000
Total Other Income	1,442,000	471,000
Income/(Loss) before Income Taxes	(19,989,000)	(21,110,000)
Income tax benefit	1,640,000	1,425,000
Net Loss Attributable to Theriva Biologics, Inc. and Subsidiaries	(18,349,000)	(19,685,000)
Effect of Warrant exercise price adjustment	0	(340,000)
Net Loss Attributable to Common Stockholders	$ (18,349,000)	$ (20,025,000)
Net Loss Per Share - Basic (in dollars per share)	$ (1.14)	$ (1.31)
Net Loss Per Share - Diluted (in dollars per share)	$ (1.14)	$ (1.31)
Weighted average number of shares outstanding during the period - Basic (in shares)	16,107,014	15,327,328
Weighted average number of shares outstanding during the period - Diluted (in shares)	16,107,014	15,327,328
Net Loss	$ (18,349,000)	$ (19,685,000)
Gain (loss) on foreign currency translation	711,000	(679,000)
Total comprehensive loss	$ (17,638,000)	$ (20,364,000)